Public or Private? | GenomeWeb

Public or Private?

Myriad CEO Peter Meldrum wrote into the New York Times in a June 20 letter, to highlight that while the Supreme Court invalidated the company's patent claims of isolated gene sequences, the court upheld several claims on synthetic DNA. In addition, he underscores the importance of diagnostic method patents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Craig Venter's Human Longevity is deeply phenotyping individuals and capturing their genetic profiles to explore aging.

The San Francisco Business Times examines Verily's latest hires.

In Nature this week: comprehensive analysis of somatic mutations in breast cancer, and more.

A number of studies indicate that genes might influence political beliefs, Scientific American Mind reports.